Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

975 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Insect Allergy: Barriers in Training and Practice: A Work Group Report of the AAAAI Anaphylaxis Committee.
Adams K, Greenhawt M, Bingemann T, Tracy J, Brooks J, Otto H, Steigelman D, Hsieh Y, Anagnostou A, Carlson J, Demain J, Harish A, Hein N, Nanda A, Hajirawala M, Waserman S, Golden DBK. Adams K, et al. Among authors: otto h. J Allergy Clin Immunol Pract. 2025 Jan 2:S2213-2198(24)01286-8. doi: 10.1016/j.jaip.2024.12.037. Online ahead of print. J Allergy Clin Immunol Pract. 2025. PMID: 39755273
The German sickle cell disease registry reveals a surprising risk of acute splenic sequestration and an increased transfusion requirement in patients with compound heterozygous sickle cell disease HbS/β-thalassaemia and no or low HbA expression.
Allard P, Tagliaferri L, Weru V, Cario H, Lobitz S, Grosse R, Bleeke M, Oevermann L, Hakimeh D, Jarisch A, Kopp-Schneider A, Kulozik AE, Kunz JB; German Sickle Cell Disease Study Group; Lassay L. Allard P, et al. Eur J Haematol. 2024 Oct;113(4):501-509. doi: 10.1111/ejh.14259. Epub 2024 Jun 30. Eur J Haematol. 2024. PMID: 38946051
LTA4H inhibitor LYS006: Clinical PK/PD and safety in a randomized phase I clinical trial.
Loesche C, Picard D, Van Hoorick B, Schuhmann I, Jäger P, Klein K, Schuhler C, Thoma G, Markert C, Poller B, Zamurovic N, Weiss HM, Otto H, Fink M, Röhn TA. Loesche C, et al. Among authors: otto h. Clin Transl Sci. 2024 Feb;17(2):e13724. doi: 10.1111/cts.13724. Clin Transl Sci. 2024. PMID: 38407540 Free PMC article. Clinical Trial.
Randomized, double-blind, multicenter study to evaluate efficacy, safety, tolerability, and immunogenicity between AVT04 and the reference product ustekinumab in patients with moderate-to-severe chronic plaque psoriasis.
Feldman SR, Reznichenko N, Berti F, Duijzings P, Ruffieux R, Otto H, Haliduola HN, Leutz S, Stroissnig H. Feldman SR, et al. Among authors: otto h. Expert Opin Biol Ther. 2023 Jul-Dec;23(8):759-771. doi: 10.1080/14712598.2023.2235263. Epub 2023 Jul 12. Expert Opin Biol Ther. 2023. PMID: 37435850 Free article. Clinical Trial.
Using archived and biocollection samples towards deciphering the DNA virus diversity associated with rodent species in the families cricetidae and heteromyidae.
Lund MC, Larsen BB, Rowsey DM, Otto HW, Gryseels S, Kraberger S, Custer JM, Steger L, Yule KM, Harris RE, Worobey M, Van Doorslaer K, Upham NS, Varsani A. Lund MC, et al. Among authors: otto hw. Virology. 2023 Aug;585:42-60. doi: 10.1016/j.virol.2023.05.006. Epub 2023 Jun 1. Virology. 2023. PMID: 37276766 Free article.
A randomized, double-blind, 3-arm, parallel study assessing the pharmacokinetics, safety, tolerability and immunogenicity of AVT04, an ustekinumab candidate biosimilar, in healthy adults.
Wynne C, Hamilton P, McLendon K, Stroissnig H, Smith M, Duijzings P, Ruffieux R, Otto H, Sattar A, Haliduola HN, Leutz S, Berti F. Wynne C, et al. Among authors: otto h. Expert Opin Investig Drugs. 2023 May;32(5):417-427. doi: 10.1080/13543784.2023.2215426. Epub 2023 May 23. Expert Opin Investig Drugs. 2023. PMID: 37212315 Free article. Clinical Trial.
Assessing the Interchangeability of AVT02 and Humira® in Participants with Moderate‑to‑Severe Chronic Plaque Psoriasis: Pharmacokinetics, Efficacy, Safety, and Immunogenicity Results from a Multicenter, Double-Blind, Randomized, Parallel-Group Study.
Feldman SR, Kay R, Reznichenko N, Sobierska J, Dias R, Otto H, Haliduola HN, Sattar A, Ruffieux R, Stroissnig H, Berti F. Feldman SR, et al. Among authors: otto h. BioDrugs. 2023 Jul;37(4):551-567. doi: 10.1007/s40259-023-00600-x. Epub 2023 May 19. BioDrugs. 2023. PMID: 37204631 Free PMC article. Clinical Trial.
975 results